Stepping into the role: How standardized patients help shape health education - UPEI

After the Big Ten implemented a uniform athlete contract model, the SEC has followed suit, with school presidents voting Monday to standardize NIL and revenue-share agreements SEC presidents voted Monday to adopt uniform NIL and revenue-share contracts across the league, effective immediately, sources told CBS Sports. The SEC joins the Big Ten as the second power conference to adopt standardized athlete contracts. Schools can share up to $21.6 million in revenue directly with athletes this academic year, the second year of the 10-year window under the House v. NCAA settlement. Players received nearly $1.8 billion in direct revenue-share payments during the 2025-26 school year, according to the College Sports Commission. The SEC's new NIL contract includes customizable sections, sources said, but CBS Sports was not given specifics. The Big Ten drafted a standardized memorandum of understanding for its schools before the House v. NCAA settlement took effect in July 2025. The template allowed schools to tweak and customize the deals.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.